Top 10 Companies in the (S)-N-Boc-allylglycine (CAS 90600-20-7) Market (2026): Market Leaders Driving Peptide Therapeutics

MARKET INSIGHTS

Global (S)-N-Boc-allylglycine (CAS 90600-20-7) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.7 million by 2034, exhibiting a CAGR of 6.4% during the forecast period.

(S)-N-Boc-allylglycine (CAS 90600-20-7) is a non-natural, protected amino acid derivative featuring a tert-butoxycarbonyl (Boc) protecting group on the amine functionality and an allyl side chain, available in enantiomerically pure (S)-configuration. It serves as a critical chiral building block in the synthesis of complex pharmaceutical intermediates, peptidomimetics, and specialty fine chemicals, owing to its versatile reactive handle – the terminal alkene – which enables a wide range of downstream chemical transformations including metathesis, cycloaddition, and cross‑coupling reactions.

The market is witnessing steady growth driven by rising demand for enantiopure amino acid derivatives in drug discovery and development, particularly in the synthesis of protease inhibitors, antibiotics, and other bioactive peptides. Furthermore, the expanding pipeline of peptide-based therapeutics globally and increasing adoption of solid‑phase peptide synthesis (SPPS) methodologies in pharmaceutical research continue to support market expansion. Leading fine chemical and specialty reagent suppliers such as Sigma‑Aldrich (Merck KGaA), TCI Chemicals, and Bachem AG are among the key players actively supplying this compound to research institutions and pharmaceutical manufacturers worldwide.

(S)-N-Boc-allylglycine (CAS 90600-20-7) Market – View in Detailed Research Report

Top 10 Companies in the (S)-N-Boc-allylglycine (CAS 90600-20-7) Market (2026)

1. Aladdin Scientific (Shanghai Aladdin Biochemical Technology Co., Ltd.)

Headquarters: Shanghai, China
Key Offering: Research‑grade (S)-N-Boc-allylglycine with rapid catalog delivery

Aladdin Scientific is a leading supplier of specialty chemicals, offering high‑purity (S)-N-Boc-allylglycine for academic and industrial research. The company leverages its robust synthetic chemistry platform and strong distribution network to provide fast turnaround on custom orders.

Sustainability & Growth Initiatives:

• Investing in green chemistry protocols to reduce waste in asymmetric synthesis.
• Expanding GMP‑grade production to meet pharmaceutical‑grade demand.
• Partnering with academic institutions for joint development of novel peptide therapeutics.

2. Ambeed Inc.

Headquarters: New York, USA
Key Offering: GMP‑qualified (S)-N-Boc-allylglycine for API development

Ambeed specializes in custom synthesis of high‑purity building blocks for the pharmaceutical industry, providing (S)-N-Boc-allylglycine with stringent enantiomeric excess (≥98%). Their state‑of‑the‑art facilities enable rapid scale‑up for early‑stage drug candidates.

Sustainability & Growth Initiatives:

• Adopting continuous flow synthesis to improve yield and reduce energy consumption.
• Partnering with CDMOs to offer integrated supply chain solutions.
• Investing in chiral chromatography technology for faster purity verification.

3. Combi-Blocks Inc.

Headquarters: New York, USA
Key Offering: Modular synthesis of (S)-N-Boc-allylglycine and related building blocks

Combi-Blocks provides a library of chiral amino acid derivatives, including (S)-N-Boc-allylglycine, to support complex peptide synthesis. Their modular approach allows rapid customization for specific synthetic routes.

Sustainability & Growth Initiatives:

• Developing solvent‑free synthesis protocols to minimize environmental impact.
• Expanding their online catalog to enhance accessibility for CROs.
• Investing in AI‑driven process optimization for higher throughput.

4. Fluorochem Ltd.

Headquarters: London, United Kingdom
Key Offering: High‑purity (S)-N-Boc-allylglycine for medicinal chemistry

Fluorochem offers a range of specialty reagents, including (S)-N-Boc-allylglycine, tailored for medicinal chemistry and peptidomimetic research. Their strong analytical capabilities ensure consistent chiral purity.

Sustainability & Growth Initiatives:

• Implementing renewable energy sources in their manufacturing facilities.
• Providing detailed batch‑level documentation for regulatory compliance.
• Collaborating with universities to advance peptide‑based drug discovery.

5. GLP Bio (Wuhan Glpbio Technology LLC)

Headquarters: Wuhan, China
Key Offering: Research‑grade (S)-N-Boc-allylglycine with rapid delivery

GLP Bio supplies high‑quality (S)-N-Boc-allylglycine for research and early‑stage development, focusing on fast turnaround and competitive pricing.

Sustainability & Growth Initiatives:

• Optimizing synthetic routes to reduce solvent usage.
• Establishing partnerships with Chinese pharma to support domestic peptide therapeutics.
• Investing in automated purification systems for higher throughput.

6. Leap Labchem Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Custom synthesis of (S)-N-Boc-allylglycine and analogs

Leap Labchem specializes in custom synthesis of chiral building blocks, offering tailored (S)-N-Boc-allylglycine solutions for both academic and industrial clients.

Sustainability & Growth Initiatives:

• Implementing closed‑loop waste management systems.
• Expanding GMP‑grade capabilities for pharmaceutical clients.
• Collaborating with CROs to streamline early‑stage synthesis.

7. Oakwood Chemical

Headquarters: Austin, USA
Key Offering: Lab‑scale (S)-N-Boc-allylglycine for research labs

Oakwood Chemical provides high‑purity (S)-N-Boc-allylglycine in lab‑scale quantities, supporting academic and industrial research with flexible ordering.

Sustainability & Growth Initiatives:

• Adopting greener solvents in synthesis.
• Offering detailed analytical reports for each batch.
• Expanding distribution to emerging markets in Asia‑Pacific.

8. Sichuan Tongsheng Amino Acid Co., Ltd.

Headquarters: Chengdu, China
Key Offering: Bulk production of (S)-N-Boc-allylglycine for pharma manufacturing

Sichuan Tongsheng focuses on large‑scale production of high‑purity (S)-N-Boc-allylglycine, supplying major pharmaceutical manufacturers with consistent supply.

Sustainability & Growth Initiatives:

• Investing in renewable energy for manufacturing plants.
• Implementing waste‑reduction protocols in synthesis.
• Developing in‑house chiral resolution techniques.

9. Simson Pharma Limited

Headquarters: New Delhi, India
Key Offering: GMP‑grade (S)-N-Boc-allylglycine for Indian pharma market

Simson Pharma supplies GMP‑qualified (S)-N-Boc-allylglycine to support the growing Indian peptide therapeutics sector, offering competitive pricing and rapid delivery.

Sustainability & Growth Initiatives:

• Partnering with local universities for joint research.
• Adopting eco‑friendly synthesis protocols.
• Expanding capacity to meet increasing demand.

10. Toronto Research Chemicals (TRC)

Headquarters: Toronto, Canada
Key Offering: Custom and catalog supply of (S)-N-Boc-allylglycine

TRC offers a wide range of specialty reagents, including (S)-N-Boc-allylglycine, with a focus on high purity and detailed documentation for regulatory compliance.

Sustainability & Growth Initiatives:

• Implementing green chemistry principles across production.
• Providing batch‑level traceability for regulatory submissions.
• Expanding digital ordering platform for CROs.

Download FREE Sample Report: (S)-N-Boc-allylglycine (CAS 90600-20-7) Market – View in Detailed Research Report

Get Full Report: (S)-N-Boc-allylglycine (CAS 90600-20-7) Market – View in Detailed Research Report

Outlook

Over the forecast period, the (S)-N-Boc-allylglycine market is expected to experience steady growth driven by the expansion of peptide therapeutics, increasing adoption of solid‑phase peptide synthesis, and the growing demand for chiral building blocks in drug discovery. The market will see a shift towards GMP‑grade production as more pharmaceutical companies seek to scale up peptide‑based APIs, creating opportunities for suppliers that can provide high‑purity, enantiomerically pure material with comprehensive documentation.

Future Trends

• Accelerated development of stapled peptides and macrocyclic drug candidates will boost demand for allyl‑functionalized building blocks.
• Advancements in asymmetric synthesis and chiral catalysis will reduce production costs and improve scalability.
• Growing focus on sustainability and green chemistry will drive the adoption of solvent‑free and renewable‑energy‑based processes.
• Increased collaboration between specialty chemical suppliers and CDMOs will streamline supply chains for early‑stage drug discovery.
• Expansion of chemical biology and bioconjugation research will open new application areas for (S)-N-Boc-allylglycine beyond traditional peptide synthesis.